) . l  a  r  i  f  y  t  h  e  p  r  o  g  n  o  s  t  i  c  r  o  l  e  p  l  a  y  e  d  b  y   T  E  T  2   m  u  t  a  t  i  o  n  ,  e  s  p  e  c  i  a  l  l  y  h  o  m  o  z  y  g  o  u  s   m  u  t  a  t  i  o  n  ,  i  n  p  a  t  i  e  n  t  s  w  i  t  h  N  K  -A  M  L  .   I  n  t  o  t  a  l  ,  4  0  7  p  a  t  i  e  n  t  s  w  e  r  e  i  n  c  l  u  d  e  d  i  n  t  h  e  p  r  e  s  e  n  t  s  t  u  d  y  ,  a  n  d  a  l  l  m  e  t  t  h  e  f  o  l  l  o  w  i  n  g   e  l  i  g  i  b  i  l  i  t  y  c  r  i  t  e  r  i  a  :  a  g  e  o  f  ≥  1  5  y  e  a  r  s  ;  a  d  i  a  g  n  o  s  i  s  o  f  N  K  -A  M  L  ,  c  o  n  f  i  r  m  e  d  b  y  c  o  n  v  e  n  t  i  o  n  a  l   c  y  t  o  g  e  n  e  t  i  c  a  n  a  l  y  s  i  s  :  a  n  d  t  r  e  a  t  m  e  n  t  w  i  t  h  i  n  d  u  c  t  i  o  n  c  h  e  m  o  t  h  e  r  a  p  y  u  s  i  n  g  a  s  t  a  n  d  a  r  d  p  r  o  t  o  c  o  l   (  a  3  -d  a  y  c  o  u  r  s  e  o  f  a  n  t  h  r  a  c  y  c  l  i  n  e  w  i  t  h  a  7  -d  a  y  c  o  u  r  s  e  o  f  c  y  t  o  s  i  n  e  a  r  a  b  i  n  o  s  i  d  e  )  .  P  a  t  i  e  n  t  s  w  i  t  h   N  K  -A  M  L  w  e  r  e  d  i  a  g  n  o  s  e  d  b  e  t  w  e  e  n  O  c  t  o  b  e  r  1  9  9  8  a  n  d  S  e  p  t  e  m  b  e  r  2  0  1  2  i  n  s  e  v  e  n  p  a  r  t  i  c  i  p  a  t  i  n  g   i  n  s  t  i  t  u  t  e  s  .  P  a  t  i  e  n  t  s  w  h  o  a  c  h  i  e  v  e  d  c  o  m  p  l  e  t  e  r  e  m  i  s  s  i  o  n  (  C  R  )  r  e  c  e  i  v  e  d  c  o  n  s  o  l  i  d  a  t  i  o  n   c  h  e  m  o  t  h  e  r  a  p  y  w  i  t  h  o  r  w  i  t  h  o  u  t  a  l  l  o  g  e  n  e  i  c  s  t  e  m  c  e  l  l  t  r  a  n  s  p  l  a  n  t  a  t  i  o  n  (  H  C  T  )  d  e  p  e  n  d  i  n  g  o  n  t  h  e   a  v  a  i  l  a  b  i  l  i  t  y  o  f  a  m  a  t  c  h  e  d  r  e  l  a  t  e  d  o  r  u  n  r  e  l  a  t  e  d  d  o  n  o  r  .  C  r  y  o  p  r  e  s  e  r  v  e  d  b  o  n  e  m  a  r  r  o  w  o  r   p  e  r  i  p  h  e  r  a  l  b  l  o  o  d  s  a  m  p  l  e  s  t  a  k  e  n  a  t  d  i  a  g  n  o  s  i  s  w  e  r  e  a  r  c  h  i  v  e  d  b  e  f  o  r  e  g  e  n  o  m  i  c  D  N  A  e  x  t  r  a  c  t  i  o  n   u  s  i  n  g  Q  I  A  a  m  p  D  N  A  b  l  o  o  d  m  i  n  i  -k  i  t  s  (  Q  i  a  g  e  n  ,  V  a  l  e  n  c  i  a  ,  C  A  ,  U  S  A  )  f  o  l  l  o  w  i  n  g  t  h  e  m  a  n  u  f  a  c  t  u  r  e  r  '  s p  r  o  t  o  c  o  l  .  M  u  t  a  t  i  o  n  a  n  a  l  y  s  i  s  w  a  s  p  e  r  f  o  r  m  e  d  u  s  i  n  g  S  a  n  g  e  r  s  eu  e  n  c  i  n  g  e  m  p  l  o  y  i  n  g  P  C  R   m  e  t  h  o  d  o  l  o  g  y  .  T  h  e  s  eu  e  n  c  i  n  g  w  a  s  p  e  r  f  o  r  m  e  d  u  s  i  n  g  a  n  A  B  I  3  1 
Supplementary methods
The endpoints of response and survival CR was defined as the presence of a morphologically normal marrow with fewer than 5% blasts, no evidence of extramedullary leukemia, and recovery of peripheral platelet counts to at least 100 × 10 9 /L and of neutrophils to 1.0 × 10 9 /L or more, for at least 4 weeks, in the absence of chemotherapy. The relapse incidence (RI) was defined as the time from attainment of remission to the date of relapse in all patients who achieved CR, with consideration of the competing risk of death without relapse. Non-relapse mortality was defined as death occurring in the absence of relapse. Event-free survival (EFS) was defined as the time from commencement of induction chemotherapy to the date of death from any cause, relapse, or non-achievement of CR, whichever occurred first. Overall survival (OS) was defined as the time from commencement of induction chemotherapy to the date of last follow-up, or death from any cause.
Patients undergoing allogeneic HSCT were not censored at the time of transplantation.
Using the ELN classification, subjects were stratified into two categories. 
Statistical analysis
We measured TET2 mutation frequencies in NK-AML patients. We categorized TET2 mutations as single, double heterozygous, or homozygous, and compared the outcomes of such patients with those of TET2 wild-type patients. Clinical characteristics and treatment outcomes were compared by reference to TET2 mutational status. Descriptive statistics are presented as frequencies with percentages for categorical variables, and as medians with ranges for continuous variables. The chi-squared test was used to compare differences in the distributions of categorical data, and Student's t-test and logistic regression analysis were used to evaluate the significance of differences in continuous variables. Statistical significances were tested by oneway analysis of variables among three groups.
EFS and OS were estimated using Kaplan-Meier survival curves, and differences among groups were compared using the log-rank test. CT -L1777fs Abbreviations: TET, ten-eleven translocation; CR, complete remission; HCT, hematopoietic cell transplantation; RI, relapse incidence; EFS, eventfree survival; OS, overall survival; ELN, European LeukemiaNet.
Supplementary Figure S2 . Clinical outcomes by TET2 mutational status in normal-karyotype acute myeloid leukemia patients: A. overall survival; B. event-free survival; C. relapse incidence (RI) and non-relapse mortality (NRM).
